mesalamine has been researched along with HIV Coinfection in 8 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients." | 6.72 | Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients. ( Fernández-Carbia, A; Marxuach-Cuétara, AM; Ríos-Bedoya, CF; Rodríguez-Orengo, JF; Rodríguez-Torres, M; Salgado-Mercado, R, 2006) |
| "The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis." | 5.19 | The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. ( Abdel-Mohsen, M; Albright, R; Cohen, M; Deeks, SG; Dunham, RM; Gorelick, R; Hsue, PY; Huang, Y; Hunt, PW; Liegler, T; Lifson, J; Martin, JN; McCune, JM; Piatak, M; Somsouk, M; Wu, Y, 2014) |
| "Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients." | 2.72 | Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients. ( Fernández-Carbia, A; Marxuach-Cuétara, AM; Ríos-Bedoya, CF; Rodríguez-Orengo, JF; Rodríguez-Torres, M; Salgado-Mercado, R, 2006) |
| "A total of 20 IBD (14 Crohn's disease, 6 ulcerative colitis) HIV infected patients and 40 matched control seronegative IBD patients (2 controls per case) were compared regarding relapse of their disease." | 1.36 | Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. ( Baraboutis, IG; Georgiadis, D; Georgiou, O; Karamanolis, DG; Papastamopoulos, V; Rodias, M; Skoutelis, A; Viazis, N; Vlachogiannakos, J, 2010) |
| "Although infrequent, metastatic Crohn's disease should be suspected in cases of recalcitrant ulcerative conditions, even in the absence of intestinal disease." | 1.33 | Metastatic Crohn's disease mimicking genital pyoderma gangrenosum in an HIV patient. ( Avilés-Izquierdo, JA; Lázaro-Ochaita, P; Longo-Imedio, I; Suárez-Fernández, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Tanweer, S | 1 |
| Jamal, S | 1 |
| Mehra, S | 1 |
| Saqib, N | 1 |
| Ahmad, F | 1 |
| Grover, A | 1 |
| Grover, S | 1 |
| Somsouk, M | 1 |
| Dunham, RM | 1 |
| Cohen, M | 1 |
| Albright, R | 1 |
| Abdel-Mohsen, M | 1 |
| Liegler, T | 1 |
| Lifson, J | 1 |
| Piatak, M | 1 |
| Gorelick, R | 1 |
| Huang, Y | 1 |
| Wu, Y | 1 |
| Hsue, PY | 1 |
| Martin, JN | 1 |
| Deeks, SG | 1 |
| McCune, JM | 1 |
| Hunt, PW | 1 |
| Green, EK | 1 |
| Ambrose, LR | 1 |
| Webster, DP | 1 |
| Atkinson, C | 1 |
| Griffiths, P | 1 |
| Murray, CD | 1 |
| Goodman, AL | 1 |
| Michelini, Z | 1 |
| Baroncelli, S | 1 |
| Fantauzzi, A | 1 |
| Pasquale, C | 1 |
| Galluzzo, CM | 1 |
| Sanchez, M | 1 |
| Gatto, M | 1 |
| Amici, R | 1 |
| Franco, M | 1 |
| d'Ettorre, G | 1 |
| Fimiani, C | 1 |
| Mezzaroma, I | 1 |
| Vullo, V | 1 |
| Merli, M | 1 |
| Palmisano, L | 1 |
| Viazis, N | 1 |
| Vlachogiannakos, J | 1 |
| Georgiou, O | 1 |
| Rodias, M | 1 |
| Georgiadis, D | 1 |
| Papastamopoulos, V | 1 |
| Baraboutis, IG | 1 |
| Karamanolis, DG | 1 |
| Skoutelis, A | 1 |
| Avilés-Izquierdo, JA | 1 |
| Suárez-Fernández, R | 1 |
| Lázaro-Ochaita, P | 1 |
| Longo-Imedio, I | 1 |
| Rodríguez-Torres, M | 1 |
| Rodríguez-Orengo, JF | 1 |
| Ríos-Bedoya, CF | 1 |
| Fernández-Carbia, A | 1 |
| Salgado-Mercado, R | 1 |
| Marxuach-Cuétara, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy[NCT01295515] | Phase 1/Phase 2 | 7 participants (Actual) | Interventional | 2011-02-11 | Completed | ||
| Mesalamine to Reduce T Cell Activation in HIV Infection[NCT01090102] | Phase 4 | 33 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the count of participants with serious and non-serious adverse events assessed by the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading Adult Adverse Events for severity (mild/moderate/severe), expectedness (expected/unexpected), and relatedness to study drug (definitely, probably, possibly, unlikely, or unrelated). (NCT01295515)
Timeframe: Date consent signed to date off study, approximately 66 months and 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Interferon Treatment | 7 |
The outcome measure is the fold change in the ratio of HIV RNA to HIV DNA. For the pre and post interferon time point, the level of HIV RNA is divided by the level of HIV DNA and this ratio of the HIV RNA/DNA pre and post interferon is calculated to yield the fold change in HIV RNA/DNA levels. Fold change does not have units. (NCT01295515)
Timeframe: week 4 (post) and week 0 (pre)
| Intervention | fold change (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Patient #1 | Patient #2 | Patient #3 | Patient #4 | Patient #5 | Patient #6 | Patient #7 | |
| Interferon Treatment | 0.408 | 1.44 | 0.684 | 1.12 | 2.24 | 4.37 | 1.05 |
Cell associated HIV nucleic acid levels were measured using a single copy assay, and numbers of cells were quantified using a polymerase chain reaction method that detects C-C chemokine receptor type 5 (CCR5) DNA. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)
| Intervention | # of copies of DNA/million cells (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #1 HIV DNA Pre | Patient #1 HIV DNA Post | Patient #2 HIV DNA Pre | Patient #2 HIV DNA Post | Patient #3 HIV DNA Pre | Patient #3 HIV DNA Post | Patient #4 HIV DNA Pre | Patient #4 HIV DNA Post | Patient #5 HIV DNA Pre | Patient #5 HIV DNA Post | Patient #6 HIV DNA Pre | Patient #6 HIV DNA Post | Patient #7 HIV DNA Pre | Patient #7 HIV DNA Post | |
| Interferon Treatment | 1200 | 790 | 150 | 150 | 660 | 500 | 400 | 310 | 10 | 19 | 520 | 420 | 390 | 460 |
Cell associated HIV nucleic acid levels were measured using a single copy assay, and numbers of cells were quantified using a polymerase chain reaction method that detects RNA. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)
| Intervention | # of copies of HIV RNA/million cells (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #1 HIV RNA Pre | Patient #1 HIV RNA Post | Patient #2 HIV RNA Pre | Patient #2 HIV RNA Post | Patient #3 HIV RNA Pre | Patient #3 HIV RNA Post | Patient #4 HIV RNA Pre | Patient #4 HIV RNA Post | Patient #5 HIV RNA Pre | Patient #5 HIV RNA Post | Patient #6 HIV RNA Pre | Patient #6 HIV RNA Post | Patient #7 HIV RNA Pre | Patient #7 HIV RNA Post | |
| Interferon Treatment | 670 | 180 | 90 | 130 | 810 | 420 | 450 | 390 | 12 | 51 | 850 | 300 | 250 | 310 |
The outcome measure is copies of HIV RNA per ml of plasma. HIV RNA levels are measured using a polymerase chain reaction method. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)
| Intervention | copies/ml (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #1 Pre | Patient #1 Post | Patient #2 Pre | Patient #2 Post | Patient #3 Pre | Patient #3 Post | Patient #4 Pre | Patient #4 Post | Patient #6 Pre | Patient #6 Post | Patient #7 Pre | Patient #7 Post | |
| Interferon Treatment | 0.7 | 3.8 | 0.2 | .02 | 3.8 | 0.8 | .02 | 1.5 | 1.3 | 0.36 | 9.1 | 8.8 |
Log(10) change in the percentage of activated T cells during the second 12 weeks of the study (NCT01090102)
Timeframe: Week 12, Week 24
| Intervention | Log10(percentage of T cells) (Mean) |
|---|---|
| Mesalamine Then Placebo | 0.003 |
| Placebo Then Mesalamine | -0.03 |
(NCT01090102)
Timeframe: Week 0, Week 12
| Intervention | Log10(percentage of T cells) (Mean) |
|---|---|
| Mesalamine Then Placebo | 0.03 |
| Placebo Then Mesalamine | -0.01 |
3 trials available for mesalamine and HIV Coinfection
| Article | Year |
|---|---|
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colitis, Ulcerative; Cross-Sectional Stu | 2016 |
Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Chronic Disease; Colitis; Colonoscopy; Diarr | 2006 |
5 other studies available for mesalamine and HIV Coinfection
| Article | Year |
|---|---|
Multifaceted role of drugs: a potential weapon to outsmart
Topics: Antitubercular Agents; Flavins; HIV Infections; Humans; Mesalamine; Molecular Docking Simulation; My | 2022 |
Intractable diarrhoea despite immune reconstitution in an HIV positive man.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; CD4 Lymphocyte Count; Cytomeg | 2015 |
Course of inflammatory bowel disease in patients infected with human immunodeficiency virus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiretroviral Therapy, Highly Active; Azathioprine; | 2010 |
Metastatic Crohn's disease mimicking genital pyoderma gangrenosum in an HIV patient.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Crohn Disease; Diagnosis, Differential; Gran | 2005 |
Gut inflammation targeted in UCLA HIV study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis; HIV Infections; Humans; | 2000 |